President and Chief Executive Officer
Antony Mattessich joined Ocular as Chief Executive Officer in August of 2017. Prior to joining the company, he was Managing Director of Mundipharma International based in Cambridge, England. Previous to his time at Mundipharma, Antony ran the US respiratory, dermatology and pediatrics group at Novartis. He also held several positions in Bristol-Myers Squibb, among them, Managing Director roles in Malaysia/Singapore and The Netherlands, and head of operations for the international medicines group. Antony holds a BA from the University of California at Berkeley and a Masters in International affairs from Columbia University.
Chief Operating Officer
Jim Fortune has more than 25 years of senior operating experience in both public and private companies within the healthcare sector. He joined Ocular Therapeutix in 2008, also serving as Chief Operating Officer of Augmenix from 2008 until April 2014 and as COO of AccessClosure from 2008 to 2010. Previously, Mr. Fortune served in COO positions at Intrinsic Therapeutics and, prior to this, at Confluent Surgical. He also had a 17-year career in management roles of increasing responsibility within the orthopedic and neurosurgical divisions of Johnson & Johnson. Mr. Fortune received a B.S. degree in mechanical engineering from Rensselaer Polytechnic Institute.
Peter Jarrett, Ph.D.
Chief Scientific Officer
Peter Jarrett, Ph.D., has more than 30 years of R&D experience, ranging from discovery to commercialization. Dr. Jarrett joined Ocular Therapeutix in 2007. Previously, he was Vice President of R&D at Focal, subsequently being named VP of Biomaterials R&D at Genzyme upon the latter company’s acquisition of Focal. Dr. Jarrett began his career in Corporate R&D of American Cyanamid, later moving to the Davis and Geck division. At Cyanamid, Focal, Genzyme and Ocular, Dr. Jarrett developed bioresorbable polymers for medical devices and drug delivery systems, resulting in numerous patents and publications. Dr. Jarrett holds a B.A. degree in chemistry from Connecticut College and a Ph.D. degree in polymer science from the University of Connecticut Institute of Materials Science.
Chief Financial Officer – Interim
Mr. George Migausky brings more than 30 years of experience in senior financial management to Ocular Therapeutix. Mr. Migausky was Executive Vice President and Chief Financial Officer of Dyax Corp., through its $6+ billion merger with Shire plc in 2016. Previously, Mr. Migausky served as the CFO of Wellstat Management Company, a firm responsible for strategy and operations of an affiliated group of five life science companies. Prior to this, he held CFO positions at several public and private companies, including IGEN International, Inc., where he played a pivotal role in the company’s IPO and subsequent $1.5 billion merger with F. Hoffman La Roche. Mr. Migausky is on the Boards of Dimension Therapeutics, Inc. and Hyperion Catalysis International, and is a trustee at the Massachusetts Ear and Eye Infirmary. He received his M.B.A. degree from Babson College and B.S. degree from Boston College.
Daniel Bollag, Ph.D.
Senior Vice President, Regulatory Affairs, Pharmacovigilance and Quality
Daniel Bollag, Ph.D., brings over 25 years of R&D and executive regulatory leadership experience to Ocular Therapeutix, having most recently served as Senior Vice President of Regulatory Affairs, Pharmacovigilance & Quality at Ariad Pharmaceuticals. During his tenure at Ariad, his responsibilities included the regulatory oversight of Iclusig® (ponatinib) and Alunbrig™ (brigatinib) from Phase 1 through accelerated regulatory approvals. Previously, Dan served as Vice President of Regulatory Affairs at Genzyme where his work included the approval of Mozobil®. Before Genzyme, held leadership positions at Sanofi-Aventis, Bristol-Myers Squibb and Merck & Co. Dan earned undergraduate degrees at the Pennsylvania State University and a doctorate in biochemistry at Cornell University.
Vice President, Marketing & Commercial Operations
Scott Corning has more than 18 years of ophthalmic medical device and pharmaceutical marketing experience covering a range of ophthalmic surgical equipment, diagnostic devices and pharmaceuticals. Prior to joining Ocular Therapeutix in 2010, Mr. Corning held marketing management positions at Alcon in both the surgical and pharmaceutical divisions, and prior to that at Summit Technology, and Euroclear in Brussels. Mr. Corning earned a B.A. degree from Wesleyan University and received an M.S./M.A. degree in management and international relations from Boston University in Brussels, Belgium.
Vice President, Product Development
Art has more than 20 years of biomaterials, medical device and biotech experience in both public and private companies, with a strong record of developing technologies from bench top through commercialization. Prior to joining Ocular Therapeutix in 2011, Mr. Driscoll was Vice President of BioSurgery R&D for Covidien’s Surgical Solutions business and previously held senior management positions at Confluent Surgical and Boston Scientific. Mr. Driscoll has a B.S degree in industrial technology and was a candidate for an M.S. degree in plastics engineering from the University of Lowell.